IP Library › Granted Patent US 7,438,910
Granted Patent B2
US 7,438,910 · App. 10/656,769 · Granted Oct 21, 2008

Therapeutic human anti-IL1-R1 monoclonal antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,438,910
App. No.
10/656,769
Granted
Oct 21, 2008
Kind
B2
Abstract

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Claims (36)

1. An isolated antibody or an antigen binding fragment thereof, that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 16, or wherein said antigen binding fragment comprises an N-terminal or C-terminal deletion of SEQ ID NO: 16 and wherein said antigen binding fragment comprises at least SEQ ID NO: 63, SEQ ID NO:66, and SEQ ID NO: 69.

2. An isolated antibody or an antigen binding fragment thereof, that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising SEQ ID NO: 18, or wherein said antigen binding fragment comprises an N-terminal or C-terminal deletion of SEQ ID NO: 18 and wherein said antigen binding fragment comprises at least SEQ ID NO: 71, SEQ ID NO: 73, and SEQ ID NO: 75.

3. An isolated antibody or an antigen binding fragment thereof, that specifically binds human interleukin-1 receptor type 1 (IL-1R1), wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO: 16, or the antigen binding fragment thereof, and a light chain variable region comprising SEQ ID NO: 18, or the antigen binding fragment thereof, wherein the antigen binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 16 and wherein said antigen binding fragment of the heavy chain variable region comprises at least SEQ ID NO: 63, SEQ ID NO:66, and SEQ ID NO: 69 and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 18 and wherein said antigen binding fragment of the light chain variable region comprises at least SEQ ID NO: 71, SEQ ID NO: 73, and SEQ ID NO: 75.

4. The antigen binding fragment of claim 1 , 2 , or 3 , wherein the heavy chain and light chain of the antigen binding fragment are connected by a flexible linker to form a single-chain antibody.

5. The antigen binding fragment of claim 4 , which is a single-chain Fv antibody.

6. The antigen binding fragment of claim 1 , 2 , or 3 , which is a Fab antibody fragment.

7. The antigen binding fragment of claim 1 , 2 , or 3 , which is Fab′ antibody fragment.

8. The antigen binding fragment of claim 1 , 2 , or 3 , which is a (Fab′) 2 antibody fragment.

9. The antibody or antigen binding fragment thereof, of claim 1 , 2 , or 3 , which is a fully human antibody or antigen binding fragment.

10. The antibody or antigen binding fragment thereof, of claim 1 , 2 , or 3 , wherein the antibody, or antigen binding fragment thereof, inhibits binding of IL-1 to human IL-1R1 receptor.

11. An isolated antibody comprising:

a. human heavy chain framework regions, a human heavy chain CDR1 region comprising SEQ ID NO: 63, a human heavy chain CDR2 region comprising SEQ ID NO: 66, and a human heavy chain CDR3 region comprising SEQ ID NO: 69; and

b. human light chain framework regions, a human light chain CDR1 region comprising SEQ ID NO: 71, a human light chain CDR2 region comprising SEQ ID NO: 73, and a human light chain CDR3 region comprising SEQ ID NO: 75.

12. The antibody or antigen binding fragment thereof of claim 3 , which is an IgG2 antibody or antigen binding fragment.

13. The antibody or antigen binding fragment thereof of claim 3 , which binds specifically to the amino acid sequence of SEQ ID NO: 76.

14. The antibody or antigen binding fragment thereof of claim 3 , wherein the antibody or antigen binding fragment thereof binds specifically to a portion of the amino acid sequence of human IL-1R1, wherein the portion of the amino acid sequence to which the antibody specifically binds comprises the amino acid sequence YSV.

15. A composition comprising a pharmaceutically acceptable carrier, excipient or diluent, and the antibody or antigen binding fragment thereof of claim 3 .

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or diluent and a therapeutically effective amount of the antibody or antigen binding fragment thereof of claim 3 .

17. An isolated antibody or an antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 80, or wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of SEQ ID NO: 80 and wherein said antigen binding fragment comprises at least SEQ ID NO: 63, SEQ ID NO: 66, and SEQ ID NO: 69.

18. An isolated antibody or antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 81, or wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of SEQ ID NO: 81 and wherein said antigen binding fragment comprises at least SEQ ID NO: 71, SEQ ID NO: 73, and SEQ ID NO: 75.

19. An isolated antibody or antigen binding fragment thereof that specifically binds human interleukin-1 receptor type 1 (IL-1R1), wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 80 or the antigen binding fragment thereof and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 81 or the antigen binding fragment thereof, wherein the antigen-binding fragment of the heavy chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 80 and wherein said antigen binding fragment comprises at least SEQ ID NO: 63, SEQ ID NO:66, and SEQ ID NO: 69, and the antigen binding fragment of the light chain variable region comprises an N-terminal or C-terminal deletion of SEQ ID NO: 81 and wherein said antigen binding fragment comprises at least SEQ ID NO: 71, SEQ ID NO: 73, and SEQ ID NO: 75.

20. An isolated antibody that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising SEQ ID NO: 80.

21. An isolated antibody that specifically binds human interleukin-1 receptor type 1 (IL-1R1), comprising a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising SEQ ID NO: 81.

22. An isolated antibody that specifically binds human interleukin-1 receptor type 1 (IL-1R1), wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO: 80, and a light chain variable region comprising SEQ ID NO: 81.

23. The antigen binding fragment of any of claims 17 , 18 , or 19 , wherein the heavy chain and light chain are connected by a flexible linker to form a single-chain antibody.

24. The antigen binding fragment of claim 23 , which is a single-chain Fv antibody.

25. The antigen binding fragment of any of claims 17 , 18 , or 19 which is a Fab antibody fragment.

26. The antigen binding fragment of any of claims 17 , 18 , or 19 which is Fab′ antibody fragment.

27. The antigen binding fragment of any of claims 17 , 18 , or 19 which is a (Fab′) 2 antibody fragment.

28. The antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 which is a fully human antibody or antigen binding fragment.

29. The antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 wherein the antibody, or antigen binding fragment thereof, inhibits binding of IL-1 to human IL-1R1 receptor.

30. The antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 which is an IgG2 antibody.

31. The antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 which binds specifically to the amino acid sequence of SEQ ID NO: 76.

32. The antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 wherein the antibody or antigen binding fragment thereof binds specifically to a portion of the amino acid sequence of human IL-1R1, wherein the portion of the amino acid sequence to which the antibody specifically binds comprises the amino acid sequence YSV.

33. A composition comprising a pharmaceutically acceptable carrier, excipient or diluent, and the antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 .

34. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or diluent and a therapeutically effective amount of the antibody or antigen binding fragment thereof of any of claims 11 , 17 , 18 , 19 , 20 , 21 , or 22 .

Assignments (2)
MERGER Recorded Jun 2, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035767/0746 →
MERGER Recorded Aug 15, 2013
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 031016/0678 →